About co diagnostics inc - CODX
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
CODX At a Glance
Co-Diagnostics, Inc.
2401 South Foothill Drive
Salt Lake City, Utah 84109
| Phone | 1-801-438-1036 | Revenue | 770.05K | |
| Industry | Biotechnology | Net Income | -37,639,008.00 | |
| Sector | Health Technology | Employees | 132 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CODX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 29.546 |
| Price to Book Ratio | 0.456 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.116 |
| Enterprise Value to Sales | -6.29 |
| Total Debt to Enterprise Value | -0.444 |
CODX Efficiency
| Revenue/Employee | 5,833.697 |
| Income Per Employee | -285,144.00 |
| Receivables Turnover | 5.809 |
| Total Asset Turnover | 0.009 |
CODX Liquidity
| Current Ratio | 4.414 |
| Quick Ratio | 4.267 |
| Cash Ratio | 4.066 |
CODX Profitability
| Gross Margin | -208.603 |
| Operating Margin | -5,613.471 |
| Pretax Margin | -4,880.428 |
| Net Margin | -4,887.878 |
| Return on Assets | -43.055 |
| Return on Equity | -53.645 |
| Return on Total Capital | -66.66 |
| Return on Invested Capital | -52.38 |
CODX Capital Structure
| Total Debt to Total Equity | 3.963 |
| Total Debt to Total Capital | 3.812 |
| Total Debt to Total Assets | 3.023 |
| Long-Term Debt to Equity | 2.277 |
| Long-Term Debt to Total Capital | 2.19 |